This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.
This RNA therapeutics innovator for rare diseases reported a notable insider sale amid a year of dramatic share price gains.
After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results